New Drugs for Chronic Myelogenous Leukemia
Posted by rob on March 5, 2011 under Uncategorized | 
Comments are off for this article
Abstract The introduction of tyrosine kinase inhibitors (TKIs) has changed the landscape of therapy for chronic myelogenous leukemia
(CML). Once considered an incurable malignancy, CML now has become a manageable chronic condition. Despite the great advances
that imatinib has brought to the treatment of CML, some patients still develop resistance to imatinib and other TKIs, such
as dasatinib and nilotinib. Furthermore, none of the clinically available TKIs is capable of eradicating leukemia stem cells
and therefore curing CML. Several new compounds have been developed in recent years in an attempt to manage TKI-resistant
CML. These include third-generation TKIs (ponatinib, danusertib) and even old compounds such as omacetaxine, which were developed
before imatinib and now …
MedWorm Message: Watch the new MedWorm demo and find out how to get all the very latest, relevant, organized information daily!